Biovica International AB (publ) Asset Resilience Ratio
Biovica International AB (publ) asset resilience ratio. Biovica International AB (publ) (BIOVIC-B) has an Asset Resilience Ratio of 28.69% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOVIC-B days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biovica International AB (publ) (2016–2025)
Asset resilience ratio of Biovica International AB (publ) from 2016 to 2025. This chart shows how Biovica International AB (publ)'s Asset Resilience Ratio has changed over time. Read how much debt does Biovica International AB (publ) carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biovica International AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Biovica International AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr16.30 Million | 28.69% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr16.30 Million | 28.69% |
Asset Resilience Insights
- Very High Liquidity: Biovica International AB (publ) maintains exceptional liquid asset reserves at 28.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biovica International AB (publ) Industry Peers by Asset Resilience Ratio
Compare Biovica International AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biovica International AB (publ) Asset Resilience Ratio by Year (2016–2025)
Biovica International AB (publ) asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Biovica International AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 0.00% | Skr0.00 ≈ $0.00 |
Skr64.95 Million ≈ $6.99 Million |
-- |
| 2024-04-30 | 19.55% | Skr25.68 Million ≈ $2.76 Million |
Skr131.41 Million ≈ $14.14 Million |
+5.38pp |
| 2023-04-30 | 14.17% | Skr24.41 Million ≈ $2.63 Million |
Skr172.29 Million ≈ $18.54 Million |
-53.21pp |
| 2022-04-30 | 67.38% | Skr102.17 Million ≈ $11.00 Million |
Skr151.63 Million ≈ $16.32 Million |
-8.08pp |
| 2021-04-30 | 75.46% | Skr145.38 Million ≈ $15.64 Million |
Skr192.65 Million ≈ $20.73 Million |
+30.27pp |
| 2020-04-30 | 45.19% | Skr40.79 Million ≈ $4.39 Million |
Skr90.26 Million ≈ $9.71 Million |
-2.07pp |
| 2019-04-30 | 47.26% | Skr28.76 Million ≈ $3.10 Million |
Skr60.86 Million ≈ $6.55 Million |
-4.89pp |
| 2018-04-30 | 52.16% | Skr42.13 Million ≈ $4.53 Million |
Skr80.77 Million ≈ $8.69 Million |
-15.21pp |
| 2017-04-30 | 67.37% | Skr65.47 Million ≈ $7.05 Million |
Skr97.18 Million ≈ $10.46 Million |
+67.43pp |
| 2016-04-30 | -0.07% | Skr-19.81K ≈ $-2.13K |
Skr28.73 Million ≈ $3.09 Million |
-- |
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more